Type 2

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

Wednesday, September 15, 2021 - 1:10pm

The double-blind, multi-center trial is assessing the safety and potential efficacy of ORMD-0801 in Type 2 diabetes patients with NASH.

Key Points: 
  • The double-blind, multi-center trial is assessing the safety and potential efficacy of ORMD-0801 in Type 2 diabetes patients with NASH.
  • "With more than half of NASH patients having diabetes, ORMD-0801 has the potential to improve outcomes for patients in both conditions.
  • The global market for drugs to treat NASH is expected to reach $84 billion by 2029.
  • Currently, no pharmacotherapy is globally approved for the treatment of NASH, and people with NASH are left with very few management options.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Leon Medical Centers Partners with Health Tech Company Rimidi, Reducing A1Cs in High-Risk Cohort of Patients with Type 2 Diabetes

Tuesday, September 14, 2021 - 2:00pm

Leon began using the Rimidi platform , which integrates directly with their Epic electronic health record (EHR), at the beginning of 2020.

Key Points: 
  • Leon began using the Rimidi platform , which integrates directly with their Epic electronic health record (EHR), at the beginning of 2020.
  • Now, 84% of those patients have been able to get their A1Cs below 9%, a key indicator of better diabetes control.
  • That's become more challengingyet more important than everduring the COVID-19 crisis" said Albert Maury, President and CEO of Leon Medical Centers.
  • Learn more about Leon Medical Centers at http://www.leonmedicalcenters.com , and at @leon.medical on Instagram, @LeonMedicalCenters on Facebook, and @LeonMedical on Twitter.

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Monday, September 13, 2021 - 3:27pm

On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.

Key Points: 
  • On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Maryland Utilities Issue Request for Proposals for the Supply of Wholesale Electric Power

Friday, September 10, 2021 - 5:00pm

The Potomac Edison Company (PE), Baltimore Gas and Electric Company (BGE), Delmarva Power, and Pepco have issued Requests for Proposals (RFPs) for full-requirements, wholesale electric power supply to meet their Standard Offer Service (SOS) obligations in their Maryland service territories.

Key Points: 
  • The Potomac Edison Company (PE), Baltimore Gas and Electric Company (BGE), Delmarva Power, and Pepco have issued Requests for Proposals (RFPs) for full-requirements, wholesale electric power supply to meet their Standard Offer Service (SOS) obligations in their Maryland service territories.
  • Each utility will provide market-based supply service to some or all of its electric customers who do not take service from competitive retail suppliers.
  • The RFPs will consist of supply contracts ranging in term from three to twenty-four months.
  • The webinar will review the general RFP structure and process, the specific utility bid plans, and the power supply contract.

Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy

Thursday, September 9, 2021 - 12:00pm

NEW YORK, and DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Type I, or early infantile, patient in the low-dose cohort of its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis. No serious adverse events considered by the investigators to be related to AXO-AAV-GM1 have been observed following the administration of GM1 gene therapy, and additional screening and enrollment of Type I patients is ongoing.

Key Points: 
  • Dosing the first Type I patient represents a major milestone for the AXO-AAV-GM1 program and for the GM1 gangliosidosis community.
  • The efforts by both Sio and our trial partners at the NIH are the culmination of our dedication to patients, said Gavin Corcoran, M.D., Chief R&D Officer of Sio Gene Therapies.
  • This milestone brings patients, now including those suffering from Type I early infantile disease, one step closer to the first approved gene therapy for this devastating pediatric lysosomal storage disorder.
  • Sio Gene Therapiescombines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.

Bel-Ray to Take Part in MINExpo 2021 in Las Vegas

Wednesday, September 8, 2021 - 9:00pm

LAS VEGAS, Sept. 8, 2021 /PRNewswire/ --Bel-Ray Total Performance Lubricants is taking part in this year's MINExpo in Las Vegas.

Key Points: 
  • LAS VEGAS, Sept. 8, 2021 /PRNewswire/ --Bel-Ray Total Performance Lubricants is taking part in this year's MINExpo in Las Vegas.
  • The mining expo runs from September 13 15 at the Las Vegas Convention Center.
  • Bel-Ray's Total Lubricant Partnership (TLP) helps companies choose the best lubricants for your machinery to reduce maintenance costs and downtime.
  • MolyLube Gear Tac Tacky Open Gear Lubricant An open gear lubricant formulated for dragline, shovel and process open gears.

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

Wednesday, September 8, 2021 - 1:05pm

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m.

Key Points: 
  • SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m.
  • In addition to presentations by Metacrines senior management team, the R&D Day will feature discussions from renowned key opinion leaders (KOLs) including:
    Juan Pablo Frias, M.D.
  • Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

 In2Bones Introduces CoLink® Mfx Midfoot Plating System

Wednesday, September 8, 2021 - 11:00am

In2Bones Global, Inc. today announces the U.S. launch of its CoLink Mfx Midfoot Plating System .

Key Points: 
  • In2Bones Global, Inc. today announces the U.S. launch of its CoLink Mfx Midfoot Plating System .
  • View the full release here: https://www.businesswire.com/news/home/20210908005338/en/
    The CoLink Mfx Midfoot Plating System from In2Bones Global simplifies and speeds surgery of the midfoot and helps improve patient outcomes.
  • Like all In2Bones products, the CoLink Mfx Midfoot Plating System features numerous design enhancements to simplify and speed the surgical procedure and improve patient outcomes, including:
    Low-profile, anatomically contoured titanium plates are designed to fit patient anatomy.
  • For more information about the new CoLink Mfx Midfoot Plating System and other In2Bones Global, Inc. extremity products, please visit www.in2bones.com .

BlackCloak Earns SOC 2 Type II Certification for its Concierge Cybersecurity & Privacy Platform

Wednesday, September 8, 2021 - 1:38pm

ORLANDO, Fla., Sept. 8, 2021 /PRNewswire/ --BlackCloak, Inc., the first Concierge Cybersecurity & Privacy Protection Platform for Executives and High-Profile Individuals, today announced its successful completion of the Service Organization Control (SOC) 2 Type II audit, earning the company SOC 2 Type II certification.

Key Points: 
  • ORLANDO, Fla., Sept. 8, 2021 /PRNewswire/ --BlackCloak, Inc., the first Concierge Cybersecurity & Privacy Protection Platform for Executives and High-Profile Individuals, today announced its successful completion of the Service Organization Control (SOC) 2 Type II audit, earning the company SOC 2 Type II certification.
  • A SOC 2 Type II report is the most comprehensive certification within the SOC protocol.
  • Executives and companies or high-profile individuals and families who want to protect their privacy, devices, and homes can feel confident that their privacy is being protected by a SOC 2 Type II certified, holistic Concierge Cybersecurity & Privacy platform.
  • Used by Fortune 500 companies across all industries, the BlackCloak Concierge Cybersecurity & Privacy Platform is a holistic solution including mobile and desktop apps as well as concierge support.